share_log

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT: Others

NeuroSense Therapeutics | EFFECT:其他
美股SEC公告 ·  2024/04/09 18:04

Moomoo AI 已提取核心信息

NeuroSense Therapeutics Ltd. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of April 8, 2024. The company, known for its focus on neurological disease treatments, had its filing accession number 0001213900-24-030479 and submission type POS AM acknowledged by the SEC. This development marks a key step for NeuroSense Therapeutics in its regulatory compliance and potential future offerings.
NeuroSense Therapeutics Ltd. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its submission effective as of April 8, 2024. The company, known for its focus on neurological disease treatments, had its filing accession number 0001213900-24-030479 and submission type POS AM acknowledged by the SEC. This development marks a key step for NeuroSense Therapeutics in its regulatory compliance and potential future offerings.
NeuroSense Therapeutics Ltd.取得了重要的里程碑,美国证券交易委员会(SEC)宣布其提交的文件自2024年4月8日起生效。该公司以专注于神经系统疾病治疗而闻名,其申报登记号为0001213900-24-030479,提交类型为POS AM,已获得美国证券交易委员会的认可。这一发展标志着NeuroSense Therapeutics在合规性和未来潜在产品方面迈出了关键一步。
NeuroSense Therapeutics Ltd.取得了重要的里程碑,美国证券交易委员会(SEC)宣布其提交的文件自2024年4月8日起生效。该公司以专注于神经系统疾病治疗而闻名,其申报登记号为0001213900-24-030479,提交类型为POS AM,已获得美国证券交易委员会的认可。这一发展标志着NeuroSense Therapeutics在合规性和未来潜在产品方面迈出了关键一步。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息